We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$201M
Cap. Flow %
-11.04%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Miscellaneous 87.94%
2 Healthcare 11.35%
3 Technology 0.45%
4 Industrials 0.13%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
276
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$201K 0.01%
3,900
-7,301
-65% -$354K
ROSG
277
DELISTED
Rosetta Genomics Ltd.
ROSG
$196K 0.01%
+13,246
New +$286K
CERE
278
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$186K 0.01%
+570,919
New +$494K
PVLA
279
Palvella Therapeutics
PVLA
$2.18B
$172K 0.01%
940
-944
-50% -$158K
EYPT icon
280
PUT
EyePoint Inc
EYPT
$316M
$165K 0.01%
+34
New +$1.32K
OXGN
281
DELISTED
OXIGENE INC COM
OXGN
$160K 0.01%
214,924
-113,507
-35% -$100K
EXEL icon
282
PUT
Exelixis
EXEL
$14.1B
$158K 0.01%
280
– –
ABUS icon
283
CALL
Arbutus Biopharma
ABUS
$1B
$156K 0.01%
351
-436
-55% -$2.39K
AVDL
284
DELISTED
Avadel Pharmaceuticals
AVDL
$148K 0.01%
+12,100
New +$189K
RMTI icon
285
Rockwell Medical
RMTI
$31.6M
$132K 0.01%
117
-305
-72% -$355K
RMTI icon
286
PUT
Rockwell Medical
RMTI
$31.6M
$132K 0.01%
1
-3
-75% -$3.49K
EYEGW
287
DELISTED
Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
$131K 0.01%
174,150
-25,850
-13% -$21.7K
TTHI
288
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$124K 0.01%
64,500
-318,100
-83% -$604K
IMNN icon
289
PUT
Imunon
IMNN
$7.86M
– –
0
– –
ATRS
290
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$105K 0.01%
866
-1,876
-68% -$2.61K
NSPH
291
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$102K 0.01%
166,234
-15,712
-9% -$21.6K
OCUL icon
292
CALL
Ocular Therapeutix
OCUL
$2.24B
$94K 0.01%
100
-15
-13% -$162
NSPR icon
293
InspireMD
NSPR
$36.1M
– –
0
– –
KERX
294
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$80K ﹤0.01%
158
– –
MBOT icon
295
Microbot Medical
MBOT
$96.7M
$77K ﹤0.01%
114
-1,145
-91% -$841K
XOMA
296
CALL
DELISTED
Xoma
XOMA
$67K ﹤0.01%
25
– –
MTEM
297
CALL
DELISTED
Molecular Templates, Inc.
MTEM
$58K ﹤0.01%
+7
New +$3.45K
KTOVW
298
DELISTED
Kitov Pharma Ltd. Warrants
KTOVW
$56K ﹤0.01%
+114,720
New +$70.7K
SCPX
299
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
0
– –
CYTR
300
CALL
DELISTED
CytRx Corp
CYTR
$45K ﹤0.01%
+28
New +$480
10 11
12
13 14

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $201M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 88% of assets, up from 83% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.